OBJECTIVE: Failure of antipsychotic medications to resolve symptoms in patients with schizophrenia creates a clinical challenge that is known as treatment resistance. The causes of treatment resistance are unknown, but it is associated with earlier age at onset and more severe cognitive deficits. The authors tested the hypothesis that white matter deficits that are involved in both neurodevelopment and severity of cognitive deficits in schizophrenia are associated with a higher risk of treatment resistance. METHODS: The study sample (N=122; mean age, 38.2 years) included schizophrenia patients at treatment initiation (N=45), patients whose symptoms were treatment responsive (N=40), and patients whose symptoms were treatment resistant (N=37), as well as healthy control subjects (N=78; mean age, 39.2 years). White matter regional vulnerability index (RVI) was tested as a predictor of treatment resistance and cognitive deficits. Higher RVI is indicative of better agreement between diffusion tensor imaging fractional anisotropy across the brain in an individual and the pattern identified by the largest-to-date meta-analysis of white matter deficits in schizophrenia. RESULTS: Patients with treatment-resistant symptoms showed the highest white matter RVI (mean=0.38 [SD=0.2]), which was significantly higher than the RVI among patients with treatment-responsive symptoms (mean=0.30 [SD=0.02]). At the onset of treatment, schizophrenia patients showed significantly higher RVI than healthy control subjects (mean=0.18 [SD=0.03] and mean=0.13 [SD=0.02], respectively). RVIs were significantly correlated with performance on processing speed and negative symptoms. CONCLUSIONS: Schizophrenia affects white matter microstructure in specific regional patterns. Susceptibility to white matter regional deficits is associated with an increased likelihood of treatment resistance. Developments to overcome schizophrenia treatment resistance should consider white matter as an important target.
OBJECTIVE: Failure of antipsychotic medications to resolve symptoms in patients with schizophrenia creates a clinical challenge that is known as treatment resistance. The causes of treatment resistance are unknown, but it is associated with earlier age at onset and more severe cognitive deficits. The authors tested the hypothesis that white matter deficits that are involved in both neurodevelopment and severity of cognitive deficits in schizophrenia are associated with a higher risk of treatment resistance. METHODS: The study sample (N=122; mean age, 38.2 years) included schizophreniapatients at treatment initiation (N=45), patients whose symptoms were treatment responsive (N=40), and patients whose symptoms were treatment resistant (N=37), as well as healthy control subjects (N=78; mean age, 39.2 years). White matter regional vulnerability index (RVI) was tested as a predictor of treatment resistance and cognitive deficits. Higher RVI is indicative of better agreement between diffusion tensor imaging fractional anisotropy across the brain in an individual and the pattern identified by the largest-to-date meta-analysis of white matter deficits in schizophrenia. RESULTS:Patients with treatment-resistant symptoms showed the highest white matter RVI (mean=0.38 [SD=0.2]), which was significantly higher than the RVI among patients with treatment-responsive symptoms (mean=0.30 [SD=0.02]). At the onset of treatment, schizophreniapatients showed significantly higher RVI than healthy control subjects (mean=0.18 [SD=0.03] and mean=0.13 [SD=0.02], respectively). RVIs were significantly correlated with performance on processing speed and negative symptoms. CONCLUSIONS:Schizophrenia affects white matter microstructure in specific regional patterns. Susceptibility to white matter regional deficits is associated with an increased likelihood of treatment resistance. Developments to overcome schizophrenia treatment resistance should consider white matter as an important target.
Entities:
Keywords:
Magnetic Resonance Imaging; Schizophrenia
Authors: Vicente Molina; Santiago Reig; Javier Sanz; Tomás Palomo; Carlos Benito; Javier Sánchez; Fernando Sarramea; Javier Pascau; Manuel Desco Journal: Schizophr Res Date: 2005-09-16 Impact factor: 4.939
Authors: Peter Kochunov; Habib Ganjgahi; Anderson Winkler; Sinead Kelly; Dinesh K Shukla; Xiaoming Du; Neda Jahanshad; Laura Rowland; Hemalatha Sampath; Binish Patel; Patricio O'Donnell; Zhiyong Xie; Sara A Paciga; Christian R Schubert; Jian Chen; Guohao Zhang; Paul M Thompson; Thomas E Nichols; L Elliot Hong Journal: Hum Brain Mapp Date: 2016-08-01 Impact factor: 5.038
Authors: Rocío Pérez-Iglesias; Diana Tordesillas-Gutiérrez; Philip K McGuire; Gareth J Barker; Roberto Roiz-Santiañez; Ignacio Mata; Enrique Marco de Lucas; Jose Manuel Rodríguez-Sánchez; Rosa Ayesa-Arriola; Jose L Vazquez-Barquero; Benedicto Crespo-Facorro Journal: Am J Psychiatry Date: 2010-02-16 Impact factor: 18.112
Authors: Robert S Kern; Keith H Nuechterlein; Michael F Green; Lyle E Baade; Wayne S Fenton; James M Gold; Richard S E Keefe; Raquelle Mesholam-Gately; Jim Mintz; Larry J Seidman; Ellen Stover; Stephen R Marder Journal: Am J Psychiatry Date: 2008-01-02 Impact factor: 18.112
Authors: Erin M Gibson; David Purger; Christopher W Mount; Andrea K Goldstein; Grant L Lin; Lauren S Wood; Ingrid Inema; Sarah E Miller; Gregor Bieri; J Bradley Zuchero; Ben A Barres; Pamelyn J Woo; Hannes Vogel; Michelle Monje Journal: Science Date: 2014-04-10 Impact factor: 47.728
Authors: Thomas P White; Rebekah Wigton; Dan W Joyce; Tracy Collier; Alex Fornito; Sukhwinder S Shergill Journal: Neuropsychopharmacology Date: 2015-09-09 Impact factor: 7.853
Authors: Natalya A Uranova; Victor M Vostrikov; Diana D Orlovskaya; Valentina I Rachmanova Journal: Schizophr Res Date: 2004-04-01 Impact factor: 4.939
Authors: Peter Kochunov; Yizhou Ma; Kathryn S Hatch; Neda Jahanshad; Paul M Thompson; Bhim M Adhikari; Heather Bruce; Andrew Van der Vaart; Eric L Goldwaser; Aris Sotiras; Mark D Kvarta; Tianzhou Ma; Shuo Chen; Thomas E Nichols; L Elliot Hong Journal: Hum Brain Mapp Date: 2022-08-30 Impact factor: 5.399
Authors: Kun Yang; Luisa Longo; Zui Narita; Nicola Cascella; Frederick C Nucifora; Jennifer M Coughlin; Gerald Nestadt; Thomas W Sedlak; Marina Mihaljevic; Min Wang; Anshel Kenkare; Anisha Nagpal; Mehk Sethi; Alexandra Kelly; Pasquale Di Carlo; Vidyulata Kamath; Andreia Faria; Peter Barker; Akira Sawa Journal: Mol Psychiatry Date: 2021-10-12 Impact factor: 13.437
Authors: Peter Kochunov; Artemis Zavaliangos-Petropulu; Neda Jahanshad; Paul M Thompson; Meghann C Ryan; Joshua Chiappelli; Shuo Chen; Xiaoming Du; Kathryn Hatch; Bhim Adhikari; Hemalatha Sampath; Stephanie Hare; Mark Kvarta; Eric Goldwaser; Fude Yang; Rene L Olvera; Peter T Fox; Joanne E Curran; John Blangero; David C Glahn; Yunlong Tan; L Elliot Hong Journal: Schizophr Bull Date: 2021-01-23 Impact factor: 9.306
Authors: Thomas M Lancaster; Stavros I Dimitriadis; Gavin Perry; Stan Zammit; Michael C O'Donovan; David E Linden Journal: Schizophr Bull Date: 2022-03-01 Impact factor: 9.306
Authors: Annie Blazer; K N Roy Chengappa; William Foran; Ashley C Parr; Charles E Kahn; Beatriz Luna; Deepak K Sarpal Journal: Psychopharmacology (Berl) Date: 2022-04-18 Impact factor: 4.415
Authors: Eric L Goldwaser; Joshua Chiappelli; Mark D Kvarta; Xiaoming Du; Zachary B Millman; Bhim M Adhikari; Hugh O'Neill; Jessica Sewell; Samantha Lightner; Shreya Vodapalli; Yizhou Ma; Heather Bruce; Shuo Chen; Yunlong Tan; Peter Kochunov; L Elliot Hong Journal: Neuropsychopharmacology Date: 2021-07-01 Impact factor: 7.853
Authors: Peter Kochunov; Fengmei Fan; Meghann C Ryan; Kathryn S Hatch; Shuping Tan; Neda Jahanshad; Paul M Thompson; Theo G M van Erp; Jessica A Turner; Shuo Chen; Xiaoming Du; Bhim Adhikari; Heather Bruce; Stephanie Hare; Eric Goldwaser; Mark Kvarta; Junchao Huang; Jinghui Tong; Yimin Cui; Baopeng Cao; Yunlong Tan; L Elliot Hong Journal: Hum Brain Mapp Date: 2020-05-28 Impact factor: 5.038
Authors: Peter Kochunov; L Elliot Hong; Emily L Dennis; Rajendra A Morey; David F Tate; Elisabeth A Wilde; Mark Logue; Sinead Kelly; Gary Donohoe; Pauline Favre; Josselin Houenou; Christopher R K Ching; Laurena Holleran; Ole A Andreassen; Laura S van Velzen; Lianne Schmaal; Julio E Villalón-Reina; Carrie E Bearden; Fabrizio Piras; Gianfranco Spalletta; Odile A van den Heuvel; Dick J Veltman; Dan J Stein; Meghann C Ryan; Yunlong Tan; Theo G M van Erp; Jessica A Turner; Liz Haddad; Talia M Nir; David C Glahn; Paul M Thompson; Neda Jahanshad Journal: Hum Brain Mapp Date: 2020-04-16 Impact factor: 5.038